Dr. Leonardo Fontanelle is an Associate Professor at the Institute of Psychiatry of Federal University of Rio de Janeiro (UFRJ), where he directed the Anxiety, Obsessive, and Compulsive Research Program from 1998 until 2018. Since 2011, he also has an appointment as a Senior Researcher at D’Or Institute for Research and Education (IDOR), a private research institution in Rio de Janeiro, Brazil. In 2019, Dr. Fontenelle became a full time Professor (level E) at the Turner Institute for Brain and Mental Health, in Monash University, Melbourne, Australia. Currently, he is the editor-in-chief of the Jornal Brasileiro de Psiquiatria and an Associate Editor of the Journal of Obsessive-Compulsive and Related Disorders. Dr. Fontenelle has authored more than 200 articles, mostly in obsessive-compulsive and anxiety related disorders. He has established the Rio de Janeiro team as one of the leading obsessive-compulsive disorder research groups in Latin America. Currently, he has ~5,400 citations (Google h-index of 40) and has given a total of 44 lectures, often as a keynote speaker, both locally and internationally. To date, Dr. Fontenelle has helped obtaining ~ R$1 million in research funding in Brazil and ~AU$ 7 million in Australia.
Dr. Dan Geller founded the Pediatric Obsessive-Compulsive Disorder (OCD) Program at Massachusetts General Hospital (MGH) in 1992. For 27 years, he has studied the causes, phenomenology, developmental expression, neural and psychiatric correlates, familial patterns, genetics, treatment and outcome of OCD and related disorders that onset in youth, including tic disorders, Tourette’s syndrome and ADHD and has produced a coherent and comprehensive body of original research. More than 200 publications include many original papers, reviews, book chapters, and new research presentations and symposia at national and international scientific meetings. At MGH, he has collected and characterized the largest sample of children and adolescents with OCD ever assembled. Dr. Geller has won competitive grants from the National Institutes of Health (K08, R01), private foundations and industry and is a founding member of the Psychiatric Genetics Consortium OCD/TS subgroup, whose goal is to identify genes responsible for OCD and delineate epigenetic mechanisms by
which genetic vulnerabilities are translated into clinical symptoms. He authored seminal research into pharmacological approaches to pediatric OCD and continues as a leading investigator of the effects of new molecules for OCD and TS and biomarkers for OCD. Most recently he has focused on inflammatory- and immune-mediated neuropsychiatric syndromes affecting children, as one cause of OCD in youth. He is the author of the American Academy of Child and Adolescent Psychiatry practice guidelines for treatment of these children and is a Distinguished Fellow of the American Academy of Child and Adolescent Psychiatry and a Fellow of the American College of Neuropsychopharmacology. Dr. Geller is an Associate Professor of Psychiatry at Harvard Medical and the inaugural incumbent of the Mittelman Family Chair in Child and Adolescent Psychiatry.
Dr. Giacomo Grassi is a psychiatrist at the Florence Brain Center, a specialized clinic for impulsive-compulsive spectrum disorders and neromudulation techniques for
neurological and psychiatric disorders. He graduated in Medicine in 2009 at the University of Florence and completed his residency program in psychiatry cum laude at the University of Florence in 2015. He obtained a Ph.D. in Neuroscience cum laude at the University of Florence in 2019 (supervisor Prof. Stefano Pallanti). As part of his residency program, he has done research activity at the Academic Medical Center in Amsterdam, The Netherlands, focusing on
deep-brain stimulation for obsessive-compulsive disorder (supervisors Prof. Damiaan Denys and Martijn Figee). In 2015 he received the Fellowship Award of the Japanese Society of
Psychiatry and Neurology. His research activity focus on impulsivity and compulsivity across neuropsychiatric disorders, neuromodulation techniques and behavioral addictions. He is
author of several scientific publications on international journals on impulsive-compulsive spectrum disorders and neuromodulation of impulsivity and compulsivity. He is deputy editor of the international peer-reviewed journal Archives of Behavioural Addiction and he is a
board member of the Italian Society of Behavioural Addictions and member of the International Society for the Study of Behavioral Addictions.
Dr. Stefano Pallanti is an Associate Professor of Psychiatry at the University of Florence in Italy where he has been Head and Director of the Clinical Psychology and Consultation Psychiatry Unit since 2009. He is Full Professor at the University of California Davis, Visiting Professor at Albert Einstein College of Medicine, and Adjunct Associate Professor at Icahn School of Medicine at Mount Sinai, where he served as the Founder and Director of the Center of Excellence for OCD, Impulsive and Behavioural Addiction. He is a Fellow Member and the Scientific Board of ECNP ( European College of Neuropsychopharmacology) and serves in its Educational Committee. He is the Advisory Council of the International Center for Autism Research and Education (Icare4autism, New York) and the International Advisory Board of the American Psychiatric Association for the Diagnostic and Statistical Manual of Mental Disorders, for its Fourth Edition (DSM-IV) and the Obsessive Compulsive Disorder Spectrum Workgroup for the DSM-V. He is a member of the board of directors of the International College for Obsessive-Compulsive Syndromes (ICOCS) and an Associate Director of the European Certificate, International Master Course in Affective Neuroscience, Universities of Maastricht, Florence, Bristol and Tel Aviv. Since May 2013 he serves as a member of board of directors for Clinical TMS Society. His current collaborative research projects are in the areas of treatment-resistant OCD, PANDAS, Anxiety in Psychosis, Anxiety Disorder in pregnancy, the puerperium and postpartum, and the ADHD – OCD spectrum. He is particularly interested in rTMS and Neuromodulation treatments. He is a member of the Editorial Board of the American Journal of Psychiatry and of the CNS Spectrums, where he is also a columnist and International Editor of American Psychiatric Publishing Inc.
Dr. Carolyn Rodriguez is an Assistant Professor of Psychiatry and Behavioral Sciences at Stanford University. After graduating from Harvard University, she completed the M.D.-Ph.D. program at Harvard Medical School-M.I.T. Dr. Rodriguez then completed her internship, residency and postdoctoral fellowship and NIMH K23 at the Columbia-Presbyterian Medical Center-NYSPI. In July 2015, she moved to Stanford University to become Director of the Translational Therapeutics/Rodriguez Lab. Her lab utilizes an interdisciplinary approach to finding treatment for patients suffering from compulsive behaviors such as Obsessive-Compulsive Disorder (OCD) and hoarding disorder. Her studies aim to gain understanding of these behaviors at multiple levels of analysis (from molecule to behavior). On the OCD front, Dr. Rodriguez is focusing on the ability of ketamine, a glutamate receptor modulator, to quickly and effectively quell obsessive thoughts. She is using a variety of imaging techniques to observe the effects of ketamine on neurotransmitter systems and brain activity in human patients, as well as investigating new treatments to extend the effects of ketamine administration. Dr. Rodriguez research interests include understanding the underlying brain mechanisms involved in hoarding behaviors and how these differ from normal collecting behavior. In addition, in order to help individuals with hoarding disorder, Dr. Rodriguez is working with government agencies to test a novel treatment intervention consisting of skills-based group treatment targeting hoarding behaviors. Her research is supported by NIMH (K23, R01), Robert Wood Johnson (Harold Amos Award), and NARSAD.